Diverse Biotech

Executive Summary

Diverse Biotech is a private, preclinical-stage biotechnology company pioneering novel drug conjugate therapies for cancer, with a particular focus on overcoming the blood-brain barrier (BBB) for conditions like glioblastoma. Founded in 2018 and headquartered in San Diego, the company's proprietary platform combines synthetic cannabinoids with targeted therapeutics to create conjugates that enhance drug delivery to the brain. This approach aims to address the significant unmet medical need in glioblastoma, where current treatments are limited by poor BBB penetration and systemic toxicity. Diverse Biotech's technology has the potential to transform the standard of care by enabling more effective and less toxic therapies for central nervous system (CNS) malignancies.

Upcoming Catalysts (preview)

• Q4 2026IND Submission for Lead Program40% success
• Q3 2026Preclinical In Vivo Efficacy Data Release65% success
• Q3 2026Series A Financing Announcement60% success